Transferosome Delivery Unlocks the Therapeutic Potential of Imiquimod for Experimental Cutaneous Leishmaniasis
Authors:
- Gabriela V. Araujo FloresGFGabriela V. Araujo Flores
- Márcia D. LaurentiMárcia D. Laurenti
- Brayan J. AnayaBrayan J. Anaya
- Italo Novais CavalloneICItalo Novais Cavallone
- Aikaterini LalatsaAikaterini Lalatsa
- Sarah Santos de Lima MelchertSarah Santos de Lima Melchert
- Thaise Y. TomokaneTTThaise Y. Tomokane
- Sergio A. SánchezSSSergio A. Sánchez
- Dolores R. SerranoDSDolores R. Serrano
- Luiz Felipe D. PasseroLuiz Felipe D. Passero
Open Access
- 16 October 2026
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2377
Abstract
Repurposing existing drugs offers an attractive strategy for neglected infectious diseases, but therapeutic efficacy may be limited by inadequate drug delivery to the site of infection. Imiquimod (IQ), a topical immunomodulatory agent, has shown potential against cutaneous leishmaniasis (CL); however, strategies to enhance its local therapeutic effect while minimizing drug exposure remain limited. Here, we developed IQ-loaded transferosomes (IQ-TFs) as nano-enabled topical delivery systems and evaluated their pharmaceutical performance, skin delivery properties, and antileishmanial efficacy against experimental CL caused by Leishmania (L.) amazonensis. IQ-TFs, prepared by thin-film hydration, showed a size of 596 ± 73 nm, low polydispersity (0.20 ± 0.02), zeta potential (−15.2 ± 1.8 mV), and high encapsulation efficiency (71.2 ± 18.7%). Encapsulation in transferosomes promoted sustained permeation and prolonged cutaneous retention of IQ, consistent with localized drug delivery. IQ-TFs markedly enhanced antileishmanial activity against both promastigotes and intracellular amastigotes. In vivo, topical IQ-TF significantly reduced parasite burden and improved infection-associated histopathological alterations. Notably, IQ-TFs achieved these effects using approximately 30-fold less IQ than the commercial 5% cream, with parasite control comparable to systemic deoxycholate amphotericin B. These findings highlight IQ transferosomes as a promising nanotechnology platform for transforming imiquimod into a more efficient low-dose topical therapy for cutaneous leishmaniasis.Keywords
Funding Information
- São Paulo Research Foundation (2014/50315-0)
- São Paulo Research Foundation (2022/15834-3)
- São Paulo Research Foundation (2024/22230-2)
- São Paulo Research Foundation (2023/01641-1)
- São Paulo Research Foundation (2026/04102-2)
- HCFMUSP-LIM50
- Complutense University of Madrid
- CNPq
This publication has 57 references indexed in Scilit:
- Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled releaseAdvanced Drug Delivery Reviews, 2024
- TLR7 Sensing by Neutrophils Is Critical for the Control of Cutaneous LeishmaniasisCell Reports, 2020
- Novel therapeutic strategies for treatment of visceral leishmaniasisDrug Discovery Today, 2013
- Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B–miltefosine-loaded nanocochleatesColloids and Surfaces B: Biointerfaces, 2013
- A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasisBiochemical and Biophysical Research Communications, 2011
- Amphotericin B Formulations and Drug TargetingJournal of Pharmaceutical Sciences, 2008
- Self-administered Topical 5% Imiquimod Cream for External Anogenital WartsArchives of Dermatology, 1998
- Cytokine induction by the immunomodulators imiquimod and S-27609Journal of Leukocyte Biology, 1995
- Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration forceBiochimica et Biophysica Acta (BBA) - Biomembranes, 1992
- The evolution of the lesion in cutaneous leishmaniasisThe Journal of Pathology, 1983